Cargando…

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

OBJECTIVE: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. METHODS: In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M., Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850652/ https://www.ncbi.nlm.nih.gov/pubmed/28968793 http://dx.doi.org/10.1093/rheumatology/kex269

Ejemplares similares

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
por: Emery, Paul, et al.
Publicado: (2017)

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
por: Emery, Paul, et al.
Publicado: (2017)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
por: Benucci, Maurizio, et al.
Publicado: (2022)

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
por: Parisi, Simone, et al.
Publicado: (2022)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study
por: Luciano, Nicoletta, et al.
Publicado: (2022)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

Treatment of LADA With Etanercept
por: Montes, Vince N., et al.
Publicado: (2012)

Etanercept-associated myelitis
por: Finke, Carsten, et al.
Publicado: (2015)

Etanercept-associated Nephropathy
por: Ammar, Awais, et al.
Publicado: (2019)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

On the decay of 110Sb, 111Sb, 112Sb, 113Sb and 114Sb
por: Sunier, J W, et al.
Publicado: (1970)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Effect of Reducing Agent on Characteristics and Antibacterial Activity of Copper-Containing Particles in Textile Materials
por: Ivanauskas, Remigijus, et al.
Publicado: (2022)

Fe-Doping Effect on Thermoelectric Properties of p-Type Bi(0.48)Sb(1.52)Te(3)
por: Mun, Hyeona, et al.
Publicado: (2015)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Etanercept in erythema nodosum leprosum
por: Santos, Julia Rocha Silva, et al.
Publicado: (2017)

Two sb or not two sb?
por: Kado, M, et al.
Publicado: (2000)

Myocardial capacity of mitochondrial oxidative phosphorylation in response to prolonged electromagnetic stress
por: Savchenko, Lesia, et al.
Publicado: (2023)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature
por: Madenidou, Anastasia-Vasiliki, et al.
Publicado: (2019)

Perispinal etanercept: Potential as an Alzheimer therapeutic
por: Griffin, W Sue T
Publicado: (2008)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_s6jji9botk6r979j2ianosqetl